Maxim Group Remains a Buy on Avenue Therapeutics (ATXI)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 16 2024
0mins
Source: Business Insider
Analyst Rating: Jason McCarthy from Maxim Group has maintained a Buy rating on Avenue Therapeutics (ATXI), which closed at $1.93, while the company reported a quarterly GAAP net loss of $2.69 million compared to a profit last year.
Company Overview: Avenue Therapeutics focuses on developing intravenous tramadol for post-operative pain management and has a Moderate Buy analyst consensus rating according to TipRanks.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
